In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approvals for sacituzumab govitecan in frontline settings for metastatic triple-negative breast cancer. Joined by Sara Tolaney, MD, MPH, a breast medical oncologist from the Dana-Farber Cancer Institute, we discussed the exciting developments in breast cancer treatment, with ASCENT-03 and ASCENT-04 trials.

Key topics covered in this episode include:

Overview of the recent FDA approvals for antibody-drug conjugates (ADCs) in breast cancer
Detailed discussion on the ASCENT-04 trial focusing on PD-L1–positive metastatic triple-negative breast cancer
Insights into the ASCENT-03 trial for PD-L1–negative disease
Comparison of sacituzumab govitecan and datopotamab deruxtecan (Dato-DXd), including their efficacy and side effect profiles
Management strategies for common side effects such as neutropenia and diarrhea

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

⁠X/Twitter: https://x.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Join us as we explored the evolving landscape of breast cancer treatment and the importance of shared decision-making in patient care. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#TripleNegativeBreastCancer, #Sacituzumab, #ASCENT03, #ASCENT04, #OncologyBrothers

Sacituzumab +/- Pembrolizumab FDA Approval in Triple Negative Breast Cancer: ASCENT-03 / ASCENT-04

Oncology Brothers: Practice-Changing Cancer Discussions

Sacituzumab +/- Pembrolizumab FDA Approval in Triple Negative Breast Cancer: ASCENT-03 / ASCENT-04